Table 4:

Univariable Cox regression models of baseline characteristics associated with transitioning to dolutegravir-based first line ART, N = 180,956

Variable	Levels	Total, n (column %)	Transition to dolutegravir events	Time, person-years	Rate per 100 person-years (95% CI)	HR
Gender	Male	56788 (31·4)	41967	52094	805·6 (797·9–813·3)	1
	Female	124168 (68·6)	79207	153937	514·5 (511·0–518·1)	0·56 (0·56–0·57)
Baseline age (cat.),	55+	14010 (7·7)	10075	14302	704·4 (690·7–718·3)	1
years	45–54	34223 (18·9)	25720	35322	728·2 (719·3–737·1)	1·04 (1·01–1·06)
	35–44	67118 (37·1)	46514	77154	602·9 (597·4–608·4)	0·82 (0·80–0·84)
	25–34	55944 (30·9)	33822	67823	498·7 (493·4–504·0)	0·66 (0·64–0·67)
	15–24	9661 (5·3)	5043	11431	441·2 (429·1–453·5)	0·56 (0·54–0·58)
Baseline time on ART, years	Median (IQR)	3·9 (2·0 to 6·4)	-	-	-	1·01 (1·01–1·01)
Baseline most recent	>=500	70180 (38·8)	47141	83106	567·2 (562·1–572·4)	1
CD4 count (cat.),	350–499	39875 (22·0)	27399	45353	604·1 (597·0–611·3)	1·10 (1·08–1·11)
cells/µL	200–349	34093 (18·8)	23200	37544	617·9 (610·0–625·9)	1·14 (1·12–1·15)
	<200	21477 (11·9)	14139	22859	618·5 (608·4–628·8)	1·17 (1·14–1·19)
	Missing	15331 (8·5)	9295	17170	541·3 (530·4–552·5)	0·98 (0·96–1.00)
TB during follow-up	No	178426 (98·6)	121008	205179	589·8 (586·4–593·1)	1
	Yes	2530 (1·4)	166	853	194·7 (166·2–226·7)	0·41 (0·35–0·48)
Pregnancy during	No	116628 (64·5)	120826	204581	590·6 (587·3–593·9)	1
follow-up	Yes	7540 (4·2)	348	1450	239·9 (215·4–266·5)	0·40 (0·36–0·44)
In CCMDD during	No	85523 (47·3)	79942	122844	650·8 (646·3–655·3)	1
follow-up?	Yes	95433 (52·7)	41232	83187	495·7 (490·9–500·5)	0·68 (0·67–0·69)

CCMDD; the Centralised Chronic Medication Dispensing & Distribution programme (a differentiated ART delivery programme)